Figure 4
From: Engineering of chimeric peptides as antagonists for the G protein-coupled receptor, RXFP4
Agonist activities of novel chimeric analogues 14–20 compared with ΔR3/I5 in RXFP3 cells (A–C) and RXFP4 cells (D–F) as measured by changes in cAMP activity. The data are the result of n = 3–4 independent experiments and are expressed as mean ± SEM.
